Monday, February 19, 2024

Latest Cure For Parkinson’s Disease

Benefits And Risks Of Clinical Trials

Trial of new treatment for Parkinson’s disease | 7.30

Participating in a clinical trial can be a rewarding experience. Consider the following benefits when deciding if you should join a clinical trial:

  • You will have access to leading healthcare professionals, cutting-edge new treatments and high standards of care.
  • Joining a clinical trial can increase your knowledge and understanding of your disease.
  • People who take part in clinical trials are contributing to science that may benefit themselves and others. The medications that you take now are available only because people before you have volunteered in clinical trials.

Although every effort is made to ensure that clinical trials are as safe as possible, clinical trials that test new therapies are experiments and can involve risks.

Here are some of the risks to consider:

  • There may be undesirable side effects to the treatment. A health professional will explain possible risks and side effects during the informed consent process.
  • The treatment may not be effective for the participant.

Naturaltreatment For Parkinsons #6 Magnesium & Iodine:

Magnesium is vital for the health of the entire nervoussystem, especially the protective layer that surrounds the nerves . Magnesiumis also essential for the production of dopamine and helps protect dopaminergicneurons in the substantia nigra from degeneration. In addition to this, new evidence is showing that low levels of magnesium in the brain causes a build-up ofheavy metals a major factor in the development of Parkinsons, Alzheimers,epilepsy and MS. In a recent trial, 30 epileptics were given 450 mg ofmagnesium daily and this successfully controlled their seizures. Ifmagnesium can help epilepsy patients, it can certainly help Parkinsons sufferers. Worldrenowned magnesium expert and author, Dr Carolyn Dean, has both Parkinsons andAlzheimers disease in her top 55 health conditions caused by amagnesium deficiency list and says that magnesium is 100% essential for the preventionand treatment of both of these diseases Dr Carolyn Dean Interview

In regards to iodine, well-known researcher and author,Dr James Howenstein, says

Iodineis found in large quantities in the brain and the ciliary body of the eye. A lackof iodine may be involved in the production of Parkinson’s disease andglaucoma.

Inthe brain, iodine concentrates in the substantia nigra, an area of the brainthat has been associated with Parkinson’s disease.

David Brownstein M.D. 9

Best Sources of Magnesium and Iodine

-What Youll Need

1 cup of Magnesium Chloride Flakes

1 cup of Distilled Water

How Can People Cope With Parkinson’s Disease

While PD usually progresses slowly, eventually daily routines may be affectedfrom socializing with friends to earning a living and taking care of a home. These changes can be difficult to accept. Support groups can help people cope with the diseases emotional impact. These groups also can provide valuable information, advice, and experience to help people with PD, their families, and their caregivers deal with a wide range of issues, including locating doctors familiar with the disease and coping with physical limitations. A list of national organizations that can help people locate support groups in their communities appears at the end of this information. Individual or family counseling may also help people find ways to cope with PD.

People with PD may also benefit from being proactive and finding out as much as possible about the disease in order to alleviate fear of the unknown and to take a positive role in maintaining their health. Many people with PD continue to work either full- or part-time, although they may need to adjust their schedule and working environment to accommodate their symptoms.

Read Also: Most Common Parkinson’s Medications

What Will A Cure For Parkinson’s Look Like

Because Parkinson’s varies so much from person to person, there may not be a single ‘cure’.

Instead we may need a range of different therapies to meet the needs of the individual and their specific form of the condition.

This mix may include treatments, therapies and strategies that can:

  • slow or stop the progression of the condition
  • replace or repair lost or damaged brain cells
  • control and manage particular symptoms
  • diagnose Parkinson’s at the earliest possible stage.

And this could involve medical treatments, such as drugs and surgical approaches, as well as lifestyle changes, for example to diet and exercise.

Establishing Pd Research Priorities

The New Parkinson

The NINDS-organized Parkinsons Disease 2014: Advancing Research, Improving Lives conference brought together researchers, clinicians, patients, caregivers, and nonprofit organizations to develop 31 prioritized recommendations for research on PD. These recommendations are being implemented through investigator-initiated grants and several NINDS programs. NINDS and the NIHs National Institute of Environmental Health Sciences held the Parkinsons Disease: Understanding the Environment and Gene Connection workshop to identify priorities for advancing research on environmental contributors to PD.

Research recommendations for Lewy Body Dementia, including Parkinsons disease dementia, were updated during the NIH Alzheimers Disease-Related Dementias Summit 2019 .

Recommended Reading: How Do You Get Parkinson’s

What Are The Latest Approved Treatments For Parkinsons Disease

Several medicines have been approved for the treatment of Parkinsons disease. Here are some of the available medicines for Parkinsons disease:

Nuplazid 3,4

Nuplazid was approved for the treatment of patients with hallucinations and delusions associated with Parkinsons disease psychosis by the Food and Drugs Administration on April 29, 2016. On December 3, 2020 The approved an update to the prescribing information for Nuplazid that will allow the medication to be taken more easily by Parkinsons patients who have difficulty swallowing.

Ongentys 5,6

Ongentys is a medication used for the treatment of Parkinson disease. It is indicated for the treatment of adult patients with Parkinson disease. It is used as an add-on to levodopa/DOPA decarboxylase inhibitors in patients who are having fluctuations in the control of their condition.

Opicapone was approved for treating patients with Parkinsons Disease as an add-on to levodopa/DOPA decarboxylase inhibitors in patients who are having fluctuations in the control of their condition by the European Medicines Agency on June 24, 2016 and by the Food and Drug Administration on April 24, 2020.

Nourianz/Nouriast 7,8,9

Nourianz/Nouriast was approved by the Food and Drug Administration , USA, on August 27, 2019 and by the Pharmaceuticals and Medical Devices Agency , Japan, in June 2013.

Inbrija 10,11,12

Who Gets Parkinsons Disease

Risk factors for PD include:

  • Age. The average age of onset is about 70 years, and the incidence rises significantly with advancing age. However, a small percent of people with PD have early-onset disease that begins before the age of 50.
  • Sex. PD affects more men than women.
  • Heredity. People with one or more close relatives who have PD have an increased risk of developing the disease themselves. An estimated 15 to 25 percent of people with PD have a known relative with the disease. Some cases of the disease can be traced to specific genetic mutations.
  • Exposure to pesticides. Studies show an increased risk of PD in people who live in rural areas with increased pesticide use.

You May Like: Parkinson’s Education For Nurses

What Causes Parkinsons Disease

Parkinsons comes under the dementia umbrella. Its adegenerative disease of the nervous system that causes a loss of motor skillsand intentional movement. When someone has Parkinsons, the part of the brainthat controls muscular movements and mood function doesnt receive enough ofthe crucial dopamine chemical. Without enough dopamine, bodily movements,learning abilities and mood levels are severely affected. So-called normalfunctions such as speaking, writing, swallowing, walking and sleeping become difficultto perform. These challenges, combined with a lowering of mood levels is whymany Parkinsons patients suffer with depression.

Key Programs And Resources

Breakthrough clinical trial could reverse symptoms of Parkinson’s Disease

The Parkinsons Disease Biomarkers Programs , a major NINDS initiative, is aimed at discovering ways to identify individuals at risk for developing PD and Lewy Body Dementia and to track the progression of the disease. It funds research and collects human biological samples and clinical data to identify biomarkers that will speed the development of novel therapeutics for PD. Goals are improving clinical trials and earlier diagnosis and treatment. Projects are actively recruiting volunteers at sites across the U.S. NINDS also collaborates with the Michael J. Fox Foundation for Parkinsons Research on BioFIND, a project collecting biological samples and clinical data from healthy volunteers and those with PD. For more information about the PDBP and how you can get involved, please visit the PDBP website.

The NINDS Morris K. Udall Centers of Excellence for Parkinsons Disease Research program supports research centers across the country that work collaboratively to study PD disease mechanisms, the genetic contributions to PD, and potential therapeutic targets and treatment strategies.

The NINDS Intramural Research Program conducts clinical studies to better understand PD mechanisms and develop novel and improve treatments.

The NINDS Biospecimens Repositories store and distribute DNA, cells, blood samples, cerebrospinal fluid, and autopsy tissue to PD researchers around the world.

Recommended Reading: Deep Brain Stimulation For Parkinson’s Disease Success Rate

Naturalremedy For Parkinsons #7 Omega

Animal based omega-3 fatty acids are a powerful weapon inthe fight against Parkinsons disease. One of the main fatty acids, DHA, is oneof the essential building blocks for the human brain. Half of your brain andeyes are made up of fat and a large proportion of this is DHA fat.

Omega-3 fatty acids have the unique ability to cross theblood-brain barrier, something most conventional drugs cannot do. They helpincrease dopamine levels and reduce neuroinflammation in the brain, while atthe same time, stimulating neuron growth. So basically, EPA and DHA help preventbrain cell damage and keep the nervous system in tip top working order! 4

Best sources of animal based omega-3s are either fishoil, cod liver oil or krill oil. High strength krill oil is the preferred option as thiscontains a substance called Astaxanthin. Astaxanthin is a potent brain food nutrientthat has been shown to prevent neurodegeneration and inflammation of the brain.For dosages, take AT LEAST the highest recommended amount listed on the bottle the same goes with fish oil or cod liver oil. You cant overdose on thesesupplements so theres nothing to be concerned about. In fact, the more omega-3syou can get into you the better the results!

In addition to this, try and eat some cold water fattyfish such as salmon, tuna, mackerel, sardines or herring 3-4 times a week foran extra supply of DHA and EPA.

Want More Practical Articles Like This

Much more can be found inourEvery Victory Counts®manual.Its packed with up-to-date information about everything Parkinsons, plus an expanded worksheets and resources section to help you put what youve learned into action.Request your free copy of theEvery Victory Countsmanual by clicking the button below.

Thank you to our 2021 Peak Partners, Adamas, Amneal, Kyowa Kirin, and Sunovion, for helping us make printing, distributing, and shipping the Every Victory Counts manual possible.

Recommended Reading: Where Is The Lesion In Parkinson’s Disease

Parkinsons Surveys Clinical Trials And Volunteer Opportunities

PAIRing Up If you are a person with Parkinsons or a care partner to someone with Parkinsons, you are invited to participate in an online survey to address neuropsychiatric concerns in Parkinsons. The survey aims to learn about the needs and priorities for clinical care, education, support, and research as related to neuropsychiatric symptoms. To learn more and participate, .

The University of Oulu, along with collaborators from Aalborg University, Fraunhofer University, the University of Manchester, the University of Glasgow, the University of Lisbon, and the University of Melbourne, is conducting a survey for people with Parkinsons and Parkinsons care partners about self-care. Complete the survey here to share your self-care strategies and techniques. You can also review ideas submitted by others and add them to your own self-care toolbox.

Looking for a once-in-a-lifetime adventure? Pass to Pass, a nonprofit dedicated to raising Parkinsons awareness while supporting hikers living with Parkinsons, offers multi-day hiking trips on the Pacific Crest Trail in both Washington and Oregon. Participants are being recruited now for these summer 2021 events. For more details and information, visit www.PasstoPass.org or contact Bill Meyer at 509-991-1212 or .

Park Test University of Rochester

Project Euphonia LSVT Global and Project Euphonia

Surgery For Parkinsons Disease

Parkinsons: New treatment targets two nerve systems at once

Based on the severity of the condition and the medical profile, the doctor may recommend surgery as one treatment option for Parkinson’s disease.

There are several types of surgery that may be performed that can help patients with Parkinson’s disease. Most of the treatments are aimed at helping the tremor or rigidity that comes with the disease. In some patients, surgery may decrease the amount of medication that is needed to control the symptoms.

There are three types of surgeries that may be performed for Parkinson’s disease, including the following:

It is important to remember that surgery may help with symptoms of Parkinson’s disease, but does not cure the disease or stop the progression of the disease.

Don’t Miss: Are Weak Legs A Sign Of Parkinson’s

A Busy Year Ahead For Parkinsons Disease

Parkinsons disease research has ended in numerous dead ends despite substantial efforts over many years. Recently, Biogen and Sanofi scrapped their Parkinsons candidates, cipanemab and venglustat respectively, owing to lack of efficacy, and a disease-modifying therapy has yet to materialise.

But the push to find drugs that help beyond reducing symptoms continues, and Evaluate Vantage has delved into the pipeline of projects in active late-stage clinical trials. This year is shaping up to be crucial for the field, with 10 studies expected to yield data or to complete in 2021.

One target that crops up multiple times is GLP-1 this approach, traditionally employed in type 2 diabetes, is also being tested in Alzheimers. Among other avenues of research, it is hoped that gene therapy could offer a one-time cure for Parkinsons.

Repurposing

Research has suggested that GLP-1 agonists have neuroprotective benefits, and several trials of marketed diabetes drugs, as well as new GLP-1-targeting projects, are under way in Parkinsons. Some of these studies are investigator sponsored, including the most advanced, a UCL-run phase III trial of Astrazenecas Bydureon called Exenatide-PD3.

In the meantime, data are expected from several phase II studies of GLP-1 agonists, including a trial of Novo Nordisk’s Victoza, being run by Cedars-Sinai Medical in collaboration with the Danish company and The Cure Parkinson’s Trust. That study is set to complete in September.

Can Exercise Help Patients Gain Ground On Parkinsons Disease

In medicines ongoing battle with disease, technology plays a major, ever-evolving role. Advances abound in the form of new drugs, medical devices and gene therapies. But a decidedly low-tech treatment strategy for at least one disease simply requires putting one foot in front of the other literally.

The target is Parkinsons disease, a progressive movement disorder that affects around 1 million people in the United States and 10 million worldwide. While there is no cure, there are drugs to treat the symptoms of Parkinsons, including tremors, rigidity, and impairment of fine motor movements. But a growing body of evidence suggests that a powerful counter to this movement disorder may be, well, movement.

A new nationwide trial that includes the University of Colorado is putting that idea to the test. Study in Parkinson Disease of Exercise is a randomized clinical trial investigating whether regular, moderate and high-intensity exercise can slow the progression of symptoms in patients in the early stages of Parkinsons disease who have not yet begun drug treatment.

Groundwork previously laid

The study, which is underway at 29 sites in North America, builds on the findings of SPARX2. That trial concluded in 2016, with results published in 2018 in JAMA Neurology. SPARX2 was led at CU by Dr. Margaret Schenkman, then director of the Physical Therapy Program and a pioneering investigator in using physical therapy to treat Parkinsons disease.

The SPARX3 Team:

Also Check: Michael J Fox Parkinson’s Research

Parkinson’s Personality And The Perception Of Parkinson’s Disease

  • Parkinson’s Disease Guide for the Newly Diagnosed by Peter LeWittISBN: 1646110447
  • A Parkinson’s Primer by John M. VineISBN: 1589881192
  • Understanding Parkinson’s Disease by Steven H. Schechter David L. CramISBN: 1943886458
  • Parkinson’s Warrior by Nick PerniscoISBN: 9780578418230Publication Date: 2019-03-05

Complementary And Supportive Therapies

A world-first trial for Parkinson’s disease

A wide variety of complementary and supportive therapies may be used for PD, including:

A healthy diet. At this time there are no specific vitamins, minerals, or other nutrients that have any proven therapeutic value in PD. The National Institute of Neurological Disorders and Stroke and other components of the National Institutes of Health are funding research to determine if caffeine, antioxidants, and other dietary factors may be beneficial for preventing or treating PD. A normal, healthy diet can promote overall well-being for people with PD just as it would for anyone else. Eating a fiber-rich diet and drinking plenty of fluids also can help alleviate constipation. A high protein diet, however, may limit levodopas absorption.

Exercise. Exercise can help people with PD improve their mobility, flexibility, and body strength. It also can improve well-being, balance, minimize gait problems, and strengthen certain muscles so that people can speak and swallow better. General physical activity, such as walking, gardening, swimming, calisthenics, and using exercise machines, can have other benefit. People with PD should always check with their doctors before beginning a new exercise program.

Alternative approaches that are used by some individuals with PD include:

Don’t Miss: Does Parkinson’s Cause Neuropathy

Scientists Have Made A Breakthrough In The Development Of A Nasal Spray For Parkinsons Disease Treatment

Researchers from the University of York have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver Parkinsons disease treatment directly to the brain.

Parkinsons disease is a condition in which parts of the brain become progressively damaged over many years. This leads to a reduction in dopamine in the brain, which plays a vital role in regulating the movement of the body. The main symptoms include involuntary shaking, slow movement, and stiff and inflexible muscles.

What Genes Are Linked To Parkinsons Disease

Several genes have been definitively linked to PD:

  • SNCA. This gene, which makes the protein alpha-synuclein, was the first gene identified to be associated with Parkinsons. Research findings by the National Institutes of Health and other institutions prompted studies of the role of alpha-synuclein in PD, which led to the discovery that Lewy bodies seen in all cases of PD contain clumps of alpha-synuclein. This discovery revealed the link between hereditary and sporadic forms of the disease.
  • LRRK2. Mutations in LRRK2 were originally identified in several English and Basque families as a cause of a late-onset PD. Subsequent studies have identified mutations of this gene in other families with PD as well as in a small percentage of people with apparently sporadic PD. LRRK2 mutations are a major cause of PD in North Africa and the Middle East.
  • DJ-1. This gene normally helps regulate gene activity and protect cells from oxidative stress and can cause rare, early forms of PD.
  • PRKN . The parkin gene is translated into a protein that normally helps cells break down and recycle proteins.
  • PINK1. PINK1 codes for a protein active in mitochondria. Mutations in this gene appear to increase susceptibility to cellular stress. PINK1 has been linked to early forms of PD.
  • GBA . Mutations in GBA cause Gaucher disease , but different changes in this gene are associated with an increased risk for Parkinsons disease as well.

Also Check: Grants For Parkinson’s Patients

Popular Articles
Related news